Delveinsight Business Research LLP

Albany, NY -- (SBWire) -- 08/20/2018 --DelveInsight's "Actinic Keratosis - Market Insights, Epidemiology and Market Forecast 2027" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2027.

Markets Covered

- United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan

Study Period: 2016-2027

Actinic Keratosis Understanding and Treatment Algorithm

The report provides detailed understanding of the epidemiology and changing market dynamics of the Actinic Keratosis in the 7 major pharmaceutical markets for the period 2016-2027. The comprehensive details about treatment algorithms and treatment guidelines for Actinic Keratosis in the US, Europe, and Japan are also provided in the report.The report covers a descriptive overview of the Actinic Keratosis, explaining its causes and currently available therapies.

Actinic Keratosis Epidemiology

According to Skin Cancer Foundation, Actinic keratosis (AK) is defined as a precancerous crusty lesion caused by damage from exposure to ultraviolet (UV) radiation. It is considered a pre-cancer condition if left untreated could develop into a skin cancer, most often squamous cell carcinoma (SCC). AK lesions appear on areas which are most commonly exposed to sun such as the face, scalp, shoulders, neck, the back of the hands and forearms, etc. Actinic keratosis (AKs) formation on skin tend to soaks up lot of sun over the years and usually appears as a rough, dry, scaly patch or growth that forms on the skin as per defined by American Academy of Dermatology. Actinic keratosis appears to be slightly more common in men than in women.

Actinic Keratosis Product Profiles & Analysis

This part of the Actinic Keratosis report encloses the Detailed historical and forecasted market
covering 7MM from 2016-2027. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Actinic Keratosis Market Outlook

The Actinic Keratosis therapeutics market is segmented widely into three main therapies that include the
lesion directed destructive therapies (cryosurgery, curettage, laser, dermabrasion, surgery etc.), field
directed topical therapies (imiquimod, diclofenac sodium, ingenol mebutate, 5-fluorouracil) and
Photodynamic therapies (PDT) (Ameluz, Levulan Kerastick, Metvixia cream, Alacare). Besides this, certain
off-label drugs are also used, such as Colchicine and Tretinoin. According to literature review, it is estimated that US has shown an increasing trend towards Actinic Keratosis since past years. Various studies from 1971 to 2004 have shown that there is a significant rise in this disease.

Actinic Keratosis Market Share by Therapies

The increase in market size is expected due to the launch of various emerging drugs such as LEO 43204, KX01-AK-003 etc.Detailed Market size of the disease by therapies, covering United States, EU5 (Germany, Spain, Italy,
France and United Kingdom) and Japan from 2016-2027.

For Sample Pages:https://www.delveinsight.com/report-store/actinic-keratosismarket-insight-epidemiology-and-market-forecast

Reasons To Buy

- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Actinic Keratosis market

- Organize sales and marketing efforts by identifying the best opportunities for Actinic Keratosis market

- To understand the future market competition in the Actinic Keratosis market.

Table Of Content

1. Report Introduction
2. Actinic Keratosis Market Overview at a Glance
3. Disease Background and Overview: Actinic Keratosis
4. Epidemiology and Patient Population
5. Epidemiology of Actinic Keratosis by Countries
5.1. United States
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.5. France
5.6. Italy
5.7. Spain
5.8. United Kingdom
5.9. Japan
6. Current Treatment & Medical practices
7. Unmet Needs of the Actinic Keratosis
8. Marketed Therapies
8.1. Drug A: Company 1
8.2. Drug B: Company 2
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Actinic Keratosis
11.1. Drug C: Company 3
11.2. Drug D: Company 4
12. Actinic Keratosis: 7MM Market Analysis
13. Actinic Keratosis: Country-Wise Market Analysis
13.1. United States
13.2. EU-5
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer

**For detailed TOC request for sample pages**

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses

We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.